Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial

Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial

Abstract Background Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally...

Full description

Bibliographic Details
Main Authors: José Viña, Joaquín Escudero, Miquel Baquero, Mónica Cebrián, Juan Antonio Carbonell-Asíns, José Enrique Muñoz, Encarnación Satorres, Juan Carlos Meléndez, José Ferrer-Rebolleda, Mª del Puig Cózar-Santiago, Jose Manuel Santabárbara-Gómez, Mariona Jové, Reinald Pamplona, Francisco José Tarazona-Santabalbina, Consuelo Borrás
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Alzheimer’s Research & Therapy
Subjects:
Soy isoflavones
Phytoestrogens
Cognitive impairment
Amyloid-beta cingulate gyrus
Online Access:https://doi.org/10.1186/s13195-022-01097-2

Internet

https://doi.org/10.1186/s13195-022-01097-2

Similar Items